Spyre Therapeutics
SYRE
SYRE
60 hedge funds and large institutions have $123M invested in Spyre Therapeutics in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
60
Holders Change
+1
Holders Change %
+1.69%
% of All Funds
1.34%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
10
Increased
18
Reduced
16
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.07M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$2.44M |
| 3 |
RWM
Ritholtz Wealth Management
New York
|
+$2.18M |
| 4 |
BlackRock
New York
|
+$2.06M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$898K |
Top Sellers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.54M |
| 2 |
Jennison Associates
New York
|
-$1.35M |
| 3 |
Man Group
London,
United Kingdom
|
-$1.31M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$519K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$398K |
